Screener
Beam Therapeutics BEAM Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Prepaid expenses and other current assets | 55,301 | 23,478 |
| Total current assets | 1,266,953 | 1,268,688 |
| Property and equipment, net | 101,247 | 104,500 |
| Restricted cash | 6,693 | 6,676 |
| Operating lease right-of-use assets | 98,148 | 100,679 |
| Other assets | 7,757 | 634 |
| Total assets | $1,480,798 | $1,481,177 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's restricted cash?
- Beam Therapeutics (BEAM) reported restricted cash of $6.69M in Q1 2026.
- How has Beam Therapeutics's restricted cash changed year-over-year?
- Beam Therapeutics's restricted cash increased by 1.3% year-over-year, from $6.61M to $6.69M.
- What is the long-term trend for Beam Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Beam Therapeutics's restricted cash has grown at a -14.8% compound annual growth rate (CAGR), from $14.84M to $6.68M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Beam Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude